PDS Biotechnology Corp Increase (Decrease) in Restructuring Reserve
PDS Biotechnology Corp (PDSB) reported Increase (Decrease) in Restructuring Reserve of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-31.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInRestructuringReserve · last filed 2022-03-31
- PDS Biotechnology Corp increase (decrease) in restructuring reserve for the quarter ending 2021-12-31 was $0.00.
- PDS Biotechnology Corp increase (decrease) in restructuring reserve for the quarter ending 2021-09-30 was $0.00.
- PDS Biotechnology Corp increase (decrease) in restructuring reserve for the quarter ending 2021-06-30 was $0.00.
- PDS Biotechnology Corp increase (decrease) in restructuring reserve for the quarter ending 2021-03-31 was $0.00.
- PDS Biotechnology Corp increase (decrease) in restructuring reserve for fiscal 2021 was $0.00.
- PDS Biotechnology Corp increase (decrease) in restructuring reserve for fiscal 2020 was -$498.19K.
- PDS Biotechnology Corp increase (decrease) in restructuring reserve for fiscal 2019 was -$1.57M.
- PDS Biotechnology Corp increase (decrease) in restructuring reserve for fiscal 2018 was $0.00.
| Period end | Increase (Decrease) in Restructuring Reserve 3 month | Increase (Decrease) in Restructuring Reserve 6 month | Increase (Decrease) in Restructuring Reserve 6 month as first filed | Increase (Decrease) in Restructuring Reserve 9 month | Increase (Decrease) in Restructuring Reserve 9 month as first filed | Increase (Decrease) in Restructuring Reserve 12 month | Increase (Decrease) in Restructuring Reserve 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $0.00 derived: sum of 2 quarters · filed 2022-03-31 | $0.00 derived: sum of 3 quarters · filed 2022-03-31 | $0.00 10-K · filed 2022-03-31 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 | $0.00 derived: sum of 4 quarters · filed 2022-03-31 | |||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $0.00 10-Q · filed 2021-08-12 | $0.00 derived: sum of 3 quarters · filed 2022-03-31 | -$126.86K derived: sum of 4 quarters · filed 2022-03-31 | |||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-13 | $0.00 derived: sum of 2 quarters · filed 2022-03-31 | -$126.86K derived: sum of 3 quarters · filed 2022-03-31 | -$269.89K derived: sum of 4 quarters · filed 2022-03-31 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$126.86K derived: sum of 2 quarters · filed 2022-03-31 | -$269.89K derived: sum of 3 quarters · filed 2022-03-31 | -$498.19K 10-K · filed 2022-03-31 | |||
| 2020-09-30 | -$126.86K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$269.89K derived: sum of 2 quarters · filed 2021-11-10 | -$498.19K 10-Q · filed 2021-11-10 | -$858.33K derived: sum of 4 quarters · filed 2021-11-10 | |||
| 2020-06-30 | -$143.03K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$371.32K 10-Q · filed 2021-08-12 | -$731.47K derived: sum of 3 quarters · filed 2021-08-12 | -$1.16M derived: sum of 4 quarters · filed 2021-08-12 | |||
| 2020-03-31 | -$228.30K 10-Q · filed 2021-05-13 | -$588.45K derived: sum of 2 quarters · filed 2021-05-13 | -$1.01M derived: sum of 3 quarters · filed 2021-05-13 | -$1.68M derived: sum of 4 quarters · filed 2021-05-13 | |||
| 2019-12-31 | -$360.15K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | -$785.69K derived: sum of 2 quarters · filed 2021-03-18 | -$1.45M derived: sum of 3 quarters · filed 2021-03-18 | -$1.57M 10-K · filed 2021-03-18 | |||
| 2019-09-30 | -$425.54K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | -$1.09M derived: sum of 2 quarters · filed 2020-11-13 | -$1.21M 10-Q · filed 2020-11-13 | -$1.21M derived: sum of 4 quarters · filed 2020-11-13 | |||
| 2019-06-30 | -$664.72K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | -$786.40K 10-Q · filed 2020-08-13 | -$786.40K derived: sum of 3 quarters · filed 2020-08-13 | -$786.40K derived: sum of 4 quarters · filed 2020-08-13 | |||
| 2019-03-31 | -$121.67K 10-Q · filed 2020-05-13 | -$121.67K derived: sum of 2 quarters · filed 2020-05-13 | -$121.67K derived: sum of 3 quarters · filed 2020-05-13 | -$121.67K derived: sum of 4 quarters · filed 2020-05-13 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | $0.00 derived: sum of 2 quarters · filed 2020-03-27 | $0.00 derived: sum of 3 quarters · filed 2020-03-27 | $0.00 10-K · filed 2020-03-27 | $5.56M 10-K · filed 2019-02-21 | ||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $0.00 derived: sum of 2 quarters · filed 2019-11-07 | $0.00 10-Q · filed 2019-11-07 | $5.18M 10-Q · filed 2018-11-01 | $0.00 derived: sum of 4 quarters · filed 2019-11-07 | ||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $0.00 10-Q · filed 2019-08-01 | $6.12M 10-Q · filed 2018-08-01 | $0.00 derived: sum of 3 quarters · filed 2019-08-01 | $0.00 derived: sum of 4 quarters · filed 2019-08-01 | ||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-14 | $0.00 derived: sum of 2 quarters · filed 2019-05-14 | $0.00 derived: sum of 3 quarters · filed 2019-05-14 | ||||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-21 | $0.00 derived: sum of 2 quarters · filed 2019-02-21 | $0.00 10-K · filed 2019-02-21 | ||||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $0.00 10-Q · filed 2018-11-01 | |||||
| 2017-06-30 | $0.00 10-Q · filed 2018-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |